Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Abstract

The present invention relates to methods of treating the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability—hypersensitivity—hyperaesthesia—dissociative phenomena— . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.

1 - 31 . (canceled) 
     
     
         32 . A pharmaceutical composition for treating a psychotic disorder comprising:
 (a) pipamperone,   (b) risperidone or 9-hydroxyrisperidone,   and a pharmaceutically acceptable carrier,   wherein the composition provides a daily dose of 5-15 mg pipamperone.   
     
     
         33 . The pharmaceutical composition of  claim 32  for treating schizophrenia. 
     
     
         34 . The pharmaceutical composition of  claim 32 , wherein the composition provides a daily dose of 0.5-2 mg risperidone or 9-hydroxyrisperidone. 
     
     
         35 . The pharmaceutical composition of  claim 33 , wherein the composition provides a daily dose of 0.5-2 mg risperidone or 9-hydroxyrisperidone. 
     
     
         36 . The pharmaceutical composition of  claim 32  wherein the composition provides a daily dose of 5 mg pipamperone. 
     
     
         37 . The pharmaceutical composition of  claim 33  wherein the composition provides a daily dose of 5 mg pipamperone. 
     
     
         38 . The pharmaceutical composition of  claim 32  wherein the composition provides a daily dose of 10 mg pipamperone. 
     
     
         39 . The pharmaceutical composition of  claim 33  wherein the composition provides a daily dose of 10 mg pipamperone. 
     
     
         40 . The pharmaceutical composition of  claim 32  wherein the composition provides a daily dose of 15 mg pipamperone. 
     
     
         41 . The pharmaceutical composition of  claim 33  wherein the composition provides a daily dose of 15 mg pipamperone. 
     
     
         42 . The pharmaceutical composition of  claim 32 , wherein pipamperone is in the form of a pharmaceutically acceptable salt. 
     
     
         43 . The pharmaceutical composition of  claim 33 , wherein pipamperone is in the form of a pharmaceutically acceptable salt. 
     
     
         44 . The pharmaceutical composition of  claim 32 , wherein risperidone or 9-hydroxyrisperidone is in the form of a pharmaceutically acceptable salt. 
     
     
         45 . The pharmaceutical composition of  claim 33 , wherein risperidone or 9-hydroxyrisperidone is in the form of a pharmaceutically acceptable salt. 
     
     
         46 . A pharmaceutical composition comprising:
 (a) 5-15 mg pipamperone,   (b) 0.5 μg to 300 mg risperidone or 9-hydroxyrisperidone,   and a pharmaceutically acceptable carrier.   
     
     
         47 . The pharmaceutical composition of  claim 46 , wherein pipamperone, and risperidone or 9-hydroxyrisperidone are present in an amount effective to treat a psychotic disorder. 
     
     
         48 . The pharmaceutical composition of  claim 46 , wherein pipamperone, and risperidone or 9-hydroxyrisperidone are present in an amount effective to treat schizophrenia. 
     
     
         49 . The pharmaceutical composition of  claim 46 , wherein risperidone or 9-hydroxyrisperidone is present in a dose of 0.5-2 mg. 
     
     
         50 . The pharmaceutical composition of  claim 46  wherein pipamperone is present in a dose of 5 mg. 
     
     
         51 . The pharmaceutical composition of  claim 46  wherein pipamperone is present in a dose of 10 mg. 
     
     
         52 . The pharmaceutical composition of  claim 46  wherein pipamperone is present in a dose of 15 mg. 
     
     
         53 . The pharmaceutical composition of  claim 46 , wherein pipamperone is in the form of a pharmaceutically acceptable salt. 
     
     
         54 . The pharmaceutical composition of  claim 46 , wherein risperidone or 9-hydroxyrisperidone is in the form of a pharmaceutically acceptable salt.